About Agilis Biotherapeutics
Agilis Biotherapeutics is a company based in Cambridge (United States) founded in 2013 was acquired by PTC Therapeutics in July 2018.. Agilis Biotherapeutics has raised $20.67 million across 2 funding rounds from investors including PTC Therapeutics and Sands Capital Ventures. The company has 14 employees as of December 31, 2017. Agilis Biotherapeutics operates in a competitive market with competitors including Spark Therapeutics, Poseida Therapeutics, Senti Biosciences, Generation Bio and AskBio, among others.
- Headquarter Cambridge, United States
- Employees 14 as on 31 Dec, 2017
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Agilis Biotherapeutics, Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$20.67 M (USD)
in 2 rounds
-
Latest Funding Round
$12.67 M (USD), Series B
Feb 24, 2017
-
Investors
PTC Therapeutics
& 1 more
-
Employee Count
14
as on Dec 31, 2017
-
Acquired by
PTC Therapeutics
(Jul 19, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Agilis Biotherapeutics
Agilis Biotherapeutics has successfully raised a total of $20.67M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $12.67 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $12.7M
-
First Round
First Round
(07 Jan 2014)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2017 | Amount | Series B - Agilis Biotherapeutics | Valuation | Sands Capital Ventures |
|
| Jan, 2014 | Amount | Series A - Agilis Biotherapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Agilis Biotherapeutics
Agilis Biotherapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include PTC Therapeutics and Sands Capital Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth stage tech & life sciences focused VC Firm investing in Asia and the US
|
Founded Year | Domain | Location | |
|
Small molecule drugs for rare diseases are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Agilis Biotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Agilis Biotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Agilis Biotherapeutics Comparisons
Competitors of Agilis Biotherapeutics
Agilis Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spark Therapeutics, Poseida Therapeutics, Senti Biosciences, Generation Bio and AskBio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare liver and eye diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Agilis Biotherapeutics
Frequently Asked Questions about Agilis Biotherapeutics
When was Agilis Biotherapeutics founded?
Agilis Biotherapeutics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is Agilis Biotherapeutics located?
Agilis Biotherapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Agilis Biotherapeutics a funded company?
Agilis Biotherapeutics is a funded company, having raised a total of $20.67M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8M, raised on Jan 07, 2014.
How many employees does Agilis Biotherapeutics have?
As of Dec 31, 2017, the latest employee count at Agilis Biotherapeutics is 14.
What does Agilis Biotherapeutics do?
Agilis Biotherapeutics was founded in 2013 in Cambridge, United States, within the biotechnology sector. A gene therapy platform targeting rare monogenic diseases is offered, with DNA-based therapeutics designed and engineered for conditions affecting the central nervous system. Operations emphasize multigenic modalities to address underlying mechanisms. Lead programs are directed toward AADC-deficiency, Friedreichs ataxia, and Angelman syndrome, supporting therapeutic development for affected patients.
Who are the top competitors of Agilis Biotherapeutics?
Agilis Biotherapeutics's top competitors include Spark Therapeutics, Generation Bio and Harmony Biosciences.
Who are Agilis Biotherapeutics's investors?
Agilis Biotherapeutics has 2 investors. Key investors include PTC Therapeutics, and Sands Capital Ventures.